Loading stock data…
$1.36-0.07 (-4.90%)
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases.
MetaVia Inc. in the Healthcare sector is trading at $1.36 with a market capitalization of $8M. Wall Street consensus targets $19.33 (3 analysts), implying a +1321.6% move over the next 12 months. The stock is currently near its 52-week low of $0.97, remaining 35.2% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 26 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.38M↓ | -$4.03M↓ | -$2.05M↑ | -$3.48M↑ | -$4.30M |
| Net Income | -$5.32M↓ | -$3.82M↓ | -$1.93M↑ | -$3.38M↑ | -$4.00M |
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standa...